Astra-Oxford shot produces immune response in older adults

Grant Boone
October 27, 2020

British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown "encouraging" responses among elderly, as well as younger participants.

Prof Moynagh said: "Maybe some people are anxious about the speed of which we're moving but that shouldn't be a concern in terms of the process that is being followed, obviously in terms of adhering to safety and measuring how safe the various vaccines are, that process is still intact".

On Sunday, authorities announced that the first clinical trials of the "BriLife" vaccine would begin on Nov 1, as a spokesperson for the defence ministry said the "necessary approvals" had been granted.

This new poll commissioned by the Irish Pharmaceutical Healthcare Association has found 55 per cent of people would get the Covid-19 vaccine if one was available.

"The vaccine programme is progressing well".

Oxford Covid vaccine prompts immune response among. They were told to prepare for the COVID-19 vaccines from the "week commencing November 2". The hope is that the human body will then attack the novel coronavirus if it sees it.

Australia condemns invasive search of women at Doha airport
She realised it wasn't a routine passport check when she was told to follow guards downstairs with other women from her flight. Women passengers on Qatar Airways QR908 checking in to fly from Doha to Sydney were ordered by Qatar Authorities on October 2.

Annelies Wilder-Smith, professor of emerging infectious diseases at the London School of Hygiene and Tropical Medicine, said phase-three trials, which involve wide-scale testing with tens of thousands of participants, are a "prerequisite for licensing" before the vaccine can be rolled out to the masses.

"We do not know the efficacy at this point and that is why we are eagerly awaiting the phase-three trial results", she told Al Jazeera from Lucerne, Switzerland.

The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed "strong immune responses" in all adult groups during the previous stage, according to an update from Oxford.

Details of the latest findings are expected to be published shortly in a clinical journal, the Financial Times reported. The trial in Britain and others around the world had already resumed.

More than 200 vaccine candidates are now in development globally.

The candidate drug is now undergoing a much larger Phase III trial across several countries to try and establish how well it protects against coronavirus in a real-world setting.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER